JP2025503402A5 - - Google Patents
Info
- Publication number
- JP2025503402A5 JP2025503402A5 JP2024534245A JP2024534245A JP2025503402A5 JP 2025503402 A5 JP2025503402 A5 JP 2025503402A5 JP 2024534245 A JP2024534245 A JP 2024534245A JP 2024534245 A JP2024534245 A JP 2024534245A JP 2025503402 A5 JP2025503402 A5 JP 2025503402A5
- Authority
- JP
- Japan
- Prior art keywords
- cdh17
- antigen
- antibody
- sequence
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163286894P | 2021-12-07 | 2021-12-07 | |
| US63/286,894 | 2021-12-07 | ||
| US202263349258P | 2022-06-06 | 2022-06-06 | |
| US63/349,258 | 2022-06-06 | ||
| PCT/US2022/052132 WO2023107558A1 (en) | 2021-12-07 | 2022-12-07 | Cdh17 antibodies and methods of treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025503402A JP2025503402A (ja) | 2025-02-04 |
| JP2025503402A5 true JP2025503402A5 (https=) | 2026-01-14 |
Family
ID=86731159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024534245A Pending JP2025503402A (ja) | 2021-12-07 | 2022-12-07 | Ｃｄｈ１７抗体及びがんを処置する方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250051437A1 (https=) |
| EP (1) | EP4444349A4 (https=) |
| JP (1) | JP2025503402A (https=) |
| KR (1) | KR20240130093A (https=) |
| CN (1) | CN119212721A (https=) |
| AU (1) | AU2022407021A1 (https=) |
| CA (1) | CA3240301A1 (https=) |
| IL (1) | IL313267A (https=) |
| MX (1) | MX2024006968A (https=) |
| WO (1) | WO2023107558A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121941709A (zh) * | 2023-09-13 | 2026-04-28 | 艾贝乐医药科技有限公司 | 抗cdh17抗体-药物偶联物及其制备和使用方法 |
| AU2024347590A1 (en) * | 2023-09-22 | 2026-04-09 | Lepu Biopharma Co., Ltd. | Anti-cdh17 antibodies and uses thereof |
| CN120230211A (zh) * | 2023-12-29 | 2025-07-01 | 广东菲鹏制药股份有限公司 | 抗cdh17抗体或其抗原结合片段及其应用 |
| CN117567650B (zh) * | 2024-01-15 | 2024-04-02 | 中国人民解放军东部战区总医院 | 共表达细胞间黏附分子icam2的car-t细胞及其制备方法与应用 |
| CN117567651B (zh) * | 2024-01-15 | 2024-03-26 | 中国人民解放军东部战区总医院 | 协同表达血管内皮黏附分子vcam1的嵌合抗原受体及其应用 |
| TW202547885A (zh) * | 2024-04-30 | 2025-12-16 | 中國商蘇州宜聯生物醫藥有限公司 | 抗體、抗體藥物偶聯物及其用途 |
| WO2025242100A1 (zh) * | 2024-05-21 | 2025-11-27 | 康诺亚生物医药科技（成都）有限公司 | 针对cdh17的抗体及其用途 |
| WO2025242099A1 (zh) * | 2024-05-21 | 2025-11-27 | 康诺亚生物医药科技（成都）有限公司 | 针对cdh17的抗体偶联药物及其用途 |
| WO2025261511A1 (zh) * | 2024-06-21 | 2025-12-26 | 迈威(上海)生物科技股份有限公司 | 靶向cdh17的抗体和adc及其应用 |
| WO2025261505A1 (zh) * | 2024-06-21 | 2025-12-26 | 映恩生物制药（苏州）有限公司 | 一种抗cdh17的抗体药物偶联物及其应用 |
| US20260078179A1 (en) | 2024-07-18 | 2026-03-19 | Novarock Biotherapeutics, Ltd. | Cdh17 antibodies and uses thereof |
| WO2026035986A1 (en) * | 2024-08-07 | 2026-02-12 | Bighat Biosciences, Inc. | Humanized anti-cdh17 antibodies and use of the same |
| WO2026041129A1 (en) * | 2024-08-22 | 2026-02-26 | Hansoh Bio Llc | Ligand-cytotoxicity drug conjugates and pharmaceutical uses thereof |
| CN120554510A (zh) * | 2025-05-29 | 2025-08-29 | 吉林大学 | 抗钙粘蛋白-17的双表位抗体及采用其制备的抗体药物偶联物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7714016B2 (en) * | 2005-04-08 | 2010-05-11 | Medarex, Inc. | Cytotoxic compounds and conjugates with cleavable substrates |
| DK2421898T3 (en) * | 2009-04-20 | 2016-05-30 | Oxford Biotherapeutics Ltd | Cadherin-17 SPECIFIC ANTIBODIES |
| WO2014093379A1 (en) * | 2012-12-10 | 2014-06-19 | Mersana Therapeutics, Inc. | Auristatin compounds and conjugates thereof |
| CN113817059B (zh) * | 2016-01-09 | 2024-03-08 | 嘉立医疗科技(广州)有限公司 | 用于癌症治疗的钙粘蛋白-17特异性抗体和细胞毒性细胞 |
-
2022
- 2022-12-07 CA CA3240301A patent/CA3240301A1/en active Pending
- 2022-12-07 KR KR1020247022227A patent/KR20240130093A/ko active Pending
- 2022-12-07 AU AU2022407021A patent/AU2022407021A1/en active Pending
- 2022-12-07 EP EP22905077.8A patent/EP4444349A4/en active Pending
- 2022-12-07 MX MX2024006968A patent/MX2024006968A/es unknown
- 2022-12-07 US US18/717,817 patent/US20250051437A1/en active Pending
- 2022-12-07 JP JP2024534245A patent/JP2025503402A/ja active Pending
- 2022-12-07 WO PCT/US2022/052132 patent/WO2023107558A1/en not_active Ceased
- 2022-12-07 IL IL313267A patent/IL313267A/en unknown
- 2022-12-07 CN CN202280090740.1A patent/CN119212721A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11834499B1 (en) | Claudin18 antibodies and methods of treating cancer | |
| JP2025503402A5 (https=) | ||
| US20250051437A1 (en) | Cdh17 antibodies and methods of treating cancer | |
| US12065489B2 (en) | Claudin-6 antibodies and drug conjugates | |
| US20220177583A1 (en) | Claudin-6 bispecific antibodies | |
| US20250042992A1 (en) | Dlk1 antibodies and methods of treating cancer | |
| JP2024546106A5 (https=) | ||
| HK40125763A (en) | Claudin-6 antibodies and drug conjugates | |
| WO2025106822A2 (en) | P2ry8 antibodies and methods of treating cancer | |
| AU2024379016A1 (en) | P2ry8 antibodies and methods of treating cancer | |
| HK40067893B (en) | Claudin-6 antibodies and drug conjugates | |
| HK40067893A (en) | Claudin-6 antibodies and drug conjugates |